Liesenhoff, C.; Meyrl, C.; Krause, D.; Eckardt, F.; Lorger, A.; Deiters, V.; Schiefelbein, J.; Klaas, J.E.; Schworm, B.; Priglinger, S.G.;
et al. High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? Life 2025, 15, 1657.
https://doi.org/10.3390/life15111657
AMA Style
Liesenhoff C, Meyrl C, Krause D, Eckardt F, Lorger A, Deiters V, Schiefelbein J, Klaas JE, Schworm B, Priglinger SG,
et al. High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? Life. 2025; 15(11):1657.
https://doi.org/10.3390/life15111657
Chicago/Turabian Style
Liesenhoff, Caspar, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger,
and et al. 2025. "High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?" Life 15, no. 11: 1657.
https://doi.org/10.3390/life15111657
APA Style
Liesenhoff, C., Meyrl, C., Krause, D., Eckardt, F., Lorger, A., Deiters, V., Schiefelbein, J., Klaas, J. E., Schworm, B., Priglinger, S. G., & Siedlecki, J.
(2025). High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? Life, 15(11), 1657.
https://doi.org/10.3390/life15111657
